Joint Formulary & PAD

Repaglinide - Diabetes Mellitus

You are here : Home > Formulary Search > Repaglinide - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :

Documentation

Information
Antidiabetic treatments comparison- PrescQIPP resource - February 2018
Information
Blood glucose control - Treatment algorithm - June 2022.pdf

PAD Profile

ChemicalSubstance :
Repaglinide
Indication :
Diabetes Mellitus
Group Name :
Antidiabetic drugs
Keywords :
Meglitinide, Blood Glucose lowering drug, Type II
Brand Names Include :
Enyglid, Prandin
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Diabetes Mellitus
Supporting Documents :
2

Committee Recommendations (1)

07 Feb 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Repaglinide is a clinically effective and cost effective alternative for monotherapy, however is not licensed with non-metformin combinations at first intensification. No recommendation is made in the guidelines below, as there is very little usage in Surrey.

Other Indications

Below are listed other indications that Repaglinide is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.